Goéré D, Daveau C, Elias D, Boige V, Tomasic G, Bonnet S, Pocard M, Dromain C, Ducreux M, Lasser P, Malka D
Department of Surgical Oncology, Institut Gustave Roussy, 39, Rue Camille Desmoulins, 94805 Villejuif, Cedex, France.
Eur J Surg Oncol. 2008 Dec;34(12):1335-9. doi: 10.1016/j.ejso.2008.03.010. Epub 2008 May 2.
All patients with metastatic (ovarian and extraovarian) CRC who underwent resection of ovarian metastases in our institution from April 1988 to August 2006 were analyzed and the response to preoperative chemotherapy was evaluated according to the RECIST criteria, and analyzed with respect to the sites of metastases (ovarian and extraovarian).
The studied population consisted of 23 women. At presentation, 20 patients had symptoms. Preoperative chemotherapy resulted in tumor control of measurable extraovarian metastases in 65% of cases. In contrast, no objective tumor response of ovarian metastases was observed, disease stabilization was obtained in only 3 patients (13%), and progression or occurrence of new ovarian metastases were observed in 20 patients (87%) (p=0.0005). With a median follow-up of 54 months [15-229], median overall survival was 30 months, and 3-year overall survival was 18%.
Ovarian metastases are less responsive to chemotherapy compared to other sites. As these "metastatic sanctuaries" often cause symptoms, surgical resection should always be considered for ovarian metastases, even in the case of associated extraovarian metastases.
对1988年4月至2006年8月间在我院接受卵巢转移瘤切除术的所有转移性(卵巢和卵巢外)结直肠癌患者进行分析,并根据RECIST标准评估术前化疗反应,同时就转移部位(卵巢和卵巢外)进行分析。
研究人群包括23名女性。就诊时,20例患者有症状。术前化疗使65%的可测量卵巢外转移瘤实现肿瘤控制。相比之下,未观察到卵巢转移瘤有客观肿瘤反应,仅3例患者(13%)病情稳定,20例患者(87%)出现进展或新发卵巢转移瘤(p = 0.0005)。中位随访54个月[15 - 229],中位总生存期为30个月,3年总生存率为18%。
与其他部位相比,卵巢转移瘤对化疗的反应较差。由于这些“转移避难所”常引起症状,即使存在相关卵巢外转移瘤,对于卵巢转移瘤也应始终考虑手术切除。